Mapping disease-specific human protein networks

Information

  • Research Project
  • 6881918
  • ApplicationId
    6881918
  • Core Project Number
    R41GM073492
  • Full Project Number
    1R41GM073492-01
  • Serial Number
    73492
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2005 - 18 years ago
  • Project End Date
    1/31/2007 - 17 years ago
  • Program Officer Name
    EDMONDS, CHARLES G.
  • Budget Start Date
    8/1/2005 - 18 years ago
  • Budget End Date
    1/31/2007 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/29/2005 - 18 years ago
Organizations

Mapping disease-specific human protein networks

[unreadable] DESCRIPTION (provided by applicant): While the human genome sequence is known, medical advances will require knowledge of how individual genes and proteins assemble into functional biological networks. These networks are built in part through physical interactions between proteins. Protein interaction networks can now be probed using highthroughput experimental methods, yet challenges remain: data can be noisy and incomplete, and methods developed for simpler model organisms can be difficult to scale up to human. [unreadable] [unreadable] This proposal aims to determine the feasibility of mapping human networks relevant to disease by developing a joint computational / experimental approach to meeting these challenges. Specific aims include developing a statistical metric for confidence in proteomic data from high-throughput two-hybrid screens; developing computational methods for mapping networks cross-species; and generating experimental data with network exploration guided by the computational predictions. [unreadable] [unreadable] If this feasibility study is successful, work in Phase II will focus on building proof-of-principle networks for two specific disease areas. Exemplary areas are cancer, to suggest potential targets for small-molecule and antibody drugs, and infectious disease, to identify host-pathogen interaction. Success in Phase I of this project will result in improved methods for mapping disease-relevant human biological networks. Success in Phase II will result in targets for therapeutic intervention. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R41
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99816
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:99816\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CURAGEN CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    NEW HAVEN
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    065115901
  • Organization District
    UNITED STATES